Ibrutinib for Relapsed / Refractory CLL: A UK and Ireland Analysis of Outcomes in 315 patients
- , UK CLL Forum
- Jacob, A
- Bloor, A
- Whiteway, A
- Milne, AE
- Kirkwood, AA
- Hodson, A
- Duncombe, AS
- Schuh, A
- von Barsewisch, B
- Fegan, C
- Fox, CP
- Pocock, C
- William, C
- Dearden, C
- Hutchinson, C
- Balotis, C
- De Lord, C
- Kennedy, DB
- Tucker, D
- Vendenberghe, E
- Maughan, E
- Kumar, E
- McNichol, F
- Scott, F
- Forconi, F
- Campbell, G
- Follows, GA
- Pratt, G
- Knight, H
- Parry, H
- Ringshausen, I
- Whalley, I
- Nielson, J
- Allen, J
- Arnold, J
- Gribbon, J
- Wallis, J
- Blundell, J
- Cwynarski, K
- Bowles, KM
- Ewings, M
- Karanth, M
- Dyer, MJ
- Hamblin, M
- Leach, M
- Badat, M
- Mir, N
- Morley, N
- Bienz, N
- Philpott, N
DOIAbstract
In 2014, ibrutinib was made available for relapsed/refractory chronic lymphocytic leukaemia (CLL) patients. The UK CLL Forum collected data from UK/Ireland patients with a minimum of 1 year follow-up with pre-planned primary endpoints; the number of patients still on therapy at 1 year (Discontinuation Free Survival; DFS) and 1 year overall survival (OS). With a median 16 months follow-up, data on 315 patients demonstrated 1 year DFS of 73.7% and 1 year OS of 83.8%. Patients with better pre-treatment performance status (PS 0/1 vs 2+) had superior DFS (77.5% vs 61.3%;p14 days and had OS of 89.7%, while 26% of patients had dose reductions and 13% had temporary treatment breaks >14 days. We could not demonstrate a detrimental effect of dose red...
Add to ORKG